In a bid to reduce the administrative burden of managing regulatory documentation and trial information, Veeva Systems (VEEV - Free Report) recently introduced a new application for clinical research centers — Veeva Vault SiteDocs.
The solution will effectively manage regulatory documentation and trial information to enhance clinical research.
Veeva partnered with IACT Health and Penn Medicine to launch Vault SiteDocs.
More About Veeva Vault SiteDocs
Veeva Vault SiteDocs conducts high-quality, compliant clinical trials with greater visibility to researchers. The platform examines document quality, completeness and accuracy.
Strength in Product Portfolio
The company’s unique solutions include Veeva Vault, Veeva CRM, Veeva Network and VeevaOpenData. Veeva Vault is the first cloud-based content management system built specifically for the life sciences.
Veeva CRM is a customer relationship management platform that offers cloud-based solutions to reach customers on any channel. Notably, the company announced mobile innovations in the Veeva CRM platform, which provides information to field teams from any device. Furthermore, New Jersey-based Merck is increasing its use of multichannel Veeva CRM to additional markets, which includes Latin America and Asia Pacific.
Another cloud application of the company is Veeva Vault Training, which is designed to simplify role-based training across life sciences organizations as well as help quality teams remain audit-ready and compliant.
Veeva Network is a master data management platform that provides global, single-instance customer and product master solution.
Lastly, VeevaOpenData is a reference data platform.
Management has announced plans to develop an AI engine specific to commercial life sciences that will use Veeva Nitro as its data source. Management believes that AI is an important technology through which the companycan generate profits.
Earlier this year, Veeva also added customers for Vault QualityOne, which continues to make excellent progress.
The latest development is likely to enhance product portfolio in cloud-based healthcare services market.
Some of the healthcare giants that are raking billions through cloud-based services are Cerner Corporation , athenahealth and Allscripts Healthcare (MDRX - Free Report) .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In a bid to reduce the administrative burden of managing regulatory documentation and trial information, Veeva Systems (VEEV - Free Report) recently introduced a new application for clinical research centers — Veeva Vault SiteDocs.
The solution will effectively manage regulatory documentation and trial information to enhance clinical research.
Veeva partnered with IACT Health and Penn Medicine to launch Vault SiteDocs.
More About Veeva Vault SiteDocs
Veeva Vault SiteDocs conducts high-quality, compliant clinical trials with greater visibility to researchers. The platform examines document quality, completeness and accuracy.
Strength in Product Portfolio
The company’s unique solutions include Veeva Vault, Veeva CRM, Veeva Network and VeevaOpenData. Veeva Vault is the first cloud-based content management system built specifically for the life sciences.
Veeva CRM is a customer relationship management platform that offers cloud-based solutions to reach customers on any channel. Notably, the company announced mobile innovations in the Veeva CRM platform, which provides information to field teams from any device. Furthermore, New Jersey-based Merck is increasing its use of multichannel Veeva CRM to additional markets, which includes Latin America and Asia Pacific.
Another cloud application of the company is Veeva Vault Training, which is designed to simplify role-based training across life sciences organizations as well as help quality teams remain audit-ready and compliant.
Veeva Network is a master data management platform that provides global, single-instance customer and product master solution.
Lastly, VeevaOpenData is a reference data platform.
Management has announced plans to develop an AI engine specific to commercial life sciences that will use Veeva Nitro as its data source. Management believes that AI is an important technology through which the companycan generate profits.
Earlier this year, Veeva also added customers for Vault QualityOne, which continues to make excellent progress.
The latest development is likely to enhance product portfolio in cloud-based healthcare services market.
Some of the healthcare giants that are raking billions through cloud-based services are Cerner Corporation , athenahealth and Allscripts Healthcare (MDRX - Free Report) .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MDRX - FREE
Get the latest research report on VEEV - FREE